“Dosing the first patient in the registrational, tumor-agnostic Phase 2 portion of the PYNNACLE trial was an important milestone for PMV. Our team has worked diligently to initiate this global trial and I would like to thank them for their efforts,” said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma. “Rezatapopt, a first-in-class precision oncology investigational therapy, offers the potential to provide a new treatment option for patients with a TP53 Y220C mutation and KRAS wild-type advanced solid tumors.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PMVP:
- PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
- PMV Pharmaceuticals initiated with a Buy at Jefferies
- PMV Pharmaceuticals announces first patient dosed in Phase 2 PYNNACLE trial
- PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
- PMV Pharmaceuticals reports promising efficacy of rezatapopt in OC study
Questions or Comments about the article? Write to editor@tipranks.com